Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Meta Expands AI Training With Employee Activity Tracking Tools 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
ROCKVILLE, Md., Feb. 25, 2016 -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update of the Company and host investor meetings at the Cowen & Company 36th Annual Health Care Conference.
Date: Monday, March 7, 2016
Time: 2:40 p.m. ET
Place: The Boston Marriott Copley Place, Boston, MA
Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.
A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company's website at www.supernus.com. An archived replay of the webcast will be available for 60 days on the Company's website after the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of impulsive aggression in patients with ADHD. SPN-812 is being developed for treatment of ADHD.
CONTACT: Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc. Tel: (301) 838-2591 Or Investor Contact: Peter Vozzo Westwicke Partners Office: (443) 213-0505 Mobile: (443) 377-4767 Email: [email protected]
